{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:36:58Z","timestamp":1786977418199,"version":"build-2736575974"},"reference-count":15,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2025,2]]},"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n Bosutinib, a tyrosine kinase inhibitor (TKI), is effective in treating chronic myeloid leukemia (CML) patients resistant or intolerant to previous TKIs. Unlike other TKIs, bosutinib's lack of inhibition of c\u2010KIT and PDGFR may contribute to its unique tolerability profile. Similar to dasatinib, it targets Bcr\/Abl and SRC kinases, particularly Lyn, raising safety concerns. In fact, the susceptibility of Lyn \u2212\/\u2212 mice to autoimmune disorders and the deregulation of Lyn\u2010dependent pathways in patients with lupus were previously shown.<\/jats:p>\n <\/jats:sec>\n \n Aims<\/jats:title>\n This study aimed to assess the time\u2010adjusted rate (TAR) of inflammatory\/immune\u2010related adverse events in bosutinib\u2010treated patients.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We analyzed clinical data from 60 patients with a minimum follow\u2010up of three months. We used the CTCAE dictionary to identify immune\u2010related adverse events (irAEs).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Patients had a median treatment duration of 47.9\u2009months (IQR: 38.4\u2013121.8), totaling 592.7 person\u2010months. Among 33 patients (55% of the sample), we detected 94 irAEs (2.3% of total adverse events), including giant cell arteritis, psoriasis, erythema nodosum, articular pain, pleural and pericardial effusion, and three cases of recurrent sterile pneumonia. The estimated TAR of the first irAEs was 14.7 (95% CI: 10.4\u201320.7) events per 100 person\u2010years; considering repeated irAEs, the TAR was 28.4 (95% CI: 23.2\u201334.8) events per 100 person\u2010years. The median time to the first irAE was 14.8\u2009months (IQR: 7.1\u201342). These rates are higher than those observed in imatinib\u2010treated patients.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Our findings support the clinical impression of a high incidence of irAEs in bosutinib\u2010treated patients and may lead to an enhanced understanding of bosutinib's safety profile and mechanism of action.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/cam4.70580","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T02:23:21Z","timestamp":1738808601000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Inflammatory\/Immune Adverse Events in Chronic Myeloid Leukemia Patients During Treatment With Bosutinib"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9570-8843","authenticated-orcid":false,"given":"E.","family":"Agostani","sequence":"first","affiliation":[{"name":"Hematology Department Fondazione IRCCS San Gerardo Dei Tintori Monza Italy"},{"name":"Department of Medicine and Surgery University of Milano\u2010 Bicocca Monza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tassistro","sequence":"additional","affiliation":[{"name":"Bicocca Center of Bioinformatics, Biostatistics and Bioimaging (B4 Centre), department of Medicine and Surgery University of Milano\u2010Bicocca Monza Italy"},{"name":"Biostatistics and Clinical Epidemiology Fondazione IRCCS San Gerardo Dei Tintori Monza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Antolini","sequence":"additional","affiliation":[{"name":"Bicocca Center of Bioinformatics, Biostatistics and Bioimaging (B4 Centre), department of Medicine and Surgery University of Milano\u2010Bicocca Monza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6058-515X","authenticated-orcid":false,"given":"C.","family":"Gambacorti\u2010Passerini","sequence":"additional","affiliation":[{"name":"Hematology Department Fondazione IRCCS San Gerardo Dei Tintori Monza Italy"},{"name":"Department of Medicine and Surgery University of Milano\u2010 Bicocca Monza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"e_1_2_12_2_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow S.","year":"2017"},{"key":"e_1_2_12_3_1","first-page":"1644","volume-title":"Cancer: Principles & Practice of Oncology","author":"DeVita V. T.","year":"2023"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(13)62120\u20100"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0102250"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.02.032"},{"key":"e_1_2_12_7_1","first-page":"375","article-title":"SKI\u2010606, a 4\u2010Anilino\u20103\u2010Quinolinecarbonitrile Dual Inhibitor of Src and Abl Kinases, Is a Potent Antiproliferative Agent Against Chronic Myelogenous Leukemia Cells in Culture and Causes Regression of K562 Xenografts in Nude Mice","volume":"63","author":"Golas J. M.","year":"2003","journal-title":"Cancer Research"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0952\u20107915(00)00219\u20103"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074\u20107613(04)00381\u20104"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00401"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092\u20108674(95)90171\u2010X"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.2217\/ijr.14.44"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2018.02.003"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219863469"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24247"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24360"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.70580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T08:01:29Z","timestamp":1750924889000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.70580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1002\/cam4.70580"],"URL":"https:\/\/doi.org\/10.1002\/cam4.70580","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"2024-09-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70580"}}